多发性骨髓瘤自体造血干细胞移植患者的衰弱动态变化及其对生活质量的影响:GETH-TC多中心研究结果
这项前瞻性多中心研究在269例接受自体造血干细胞移植的多发性骨髓瘤成人患者中评估造血细胞移植衰弱量表的效用,在首次咨询、移植入院和+100天评估衰弱,用EQ-5D-5L测量生活质量。首次咨询时23.8%为健康、57.6%为衰弱前期、18.6%为衰弱;移植入院时32.3%患者衰弱状态发生变化;衰弱患者再入院率14.7%且生活质量显著更低(p < 0.001)。
要点
- 首次咨询时23.8%健康、57.6%衰弱前期、18.6%衰弱,衰弱与晚期疾病、较低Karnofsky体能状态和较大年龄相关。
- 移植入院时32.3%患者衰弱状态发生变化,证实衰弱具动态性。
- 衰弱患者再入院率14.7%,生活质量较其他患者显著更低(p < 0.001)。
核心结论
- 造血细胞移植衰弱量表是识别和监测接受自体造血干细胞移植的多发性骨髓瘤患者衰弱的有效工具。
- 衰弱状态随时间演变,持续评估对指导个体化照护、减少并发症及改善结局和生活质量至关重要。
研究设计与样本
- 前瞻性多中心研究,纳入269例接受自体造血干细胞移植的多发性骨髓瘤成人患者。
- 在首次咨询、移植入院和+100天评估衰弱,生活质量用EuroQol(EQ-5D-5L)问卷测量。
主要发现
- 首次咨询时23.8%为健康、57.6%为衰弱前期、18.6%为衰弱。
- 衰弱与晚期疾病分期、较低Karnofsky体能状态和较大年龄相关。
- 移植入院时32.3%患者衰弱状态发生变化。
- 衰弱患者再入院率为14.7%,生活质量较其他患者显著更低(p < 0.001)。
- 非复发死亡率差异无统计学意义,但衰弱和衰弱前期患者1年非复发死亡率分别为4.8%和3.4%,健康患者为0%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This prospective multicentre study evaluates the utility of the haematopoietic cell transplantation (HCT) Frailty Scale in 269 adults with multiple myeloma (MM) undergoing autologous haematopoietic cell transplantation (auto-HCT). Frailty was assessed in all patients at the first consultation, at transplant admission and on day +100. Quality of life (QoL) was measured using the EuroQol (EQ-5D-5L) questionnaire. At the first consultation, 23.8% were fit, 57.6% pre-frail and 18.6% frail. Frailty was associated with advanced disease stage, reduced Karnofsky Performance Status and older age. At HCT admission, 32.3% of patients showed changes in frailty status, confirming its dynamic nature. Frail patients had higher readmission rates (14.7%) and significantly lower QoL (p < 0.001) compared to others. Although differences in non-relapsed mortality (NRM) were not statistically significant, frail and pre-frail patients showed higher 1-year NRM (4.8% and 3.4%) compared to fit patients (0%). By day +100, 33.6% were fit, 55.9% pre-frail and 8.2% frail, with frail patients continuing to report poorer QoL. In conclusion, the HCT Frailty Scale is a valuable tool for identifying and monitoring frailty in MM patients undergoing auto-HCT. As frailty status evolves over time, ongoing assessment is essential to guide personalized care, reduce complications and improve outcomes and QoL.
引用
- Tolosa-Ridao C, González MB, Gómez MA, et al. Frailty dynamics and their impact on QoL in patients undergoing autologous HCT for multiple myeloma: Results from a multicentre GETH-TC study. Br J Haematol. 2025. PMID: 40796522. doi:10.1111/bjh.70068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。